CeriBell (NASDAQ:CBLL) Announces Quarterly Earnings Results, Misses Expectations By $0.08 EPS

CeriBell (NASDAQ:CBLL) announced its quarterly earnings results on Tuesday. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.08), Zacks reports.

CeriBell Stock Up 0.4 %

CBLL traded up $0.11 on Tuesday, hitting $25.54. 436,495 shares of the company’s stock were exchanged, compared to its average volume of 185,853. The firm’s 50-day simple moving average is $23.47. CeriBell has a fifty-two week low of $18.69 and a fifty-two week high of $32.75.

Analysts Set New Price Targets

Several research firms have recently weighed in on CBLL. William Blair began coverage on shares of CeriBell in a report on Tuesday, November 5th. They set an “outperform” rating for the company. Canaccord Genuity Group began coverage on shares of CeriBell in a research note on Tuesday, November 5th. They set a “buy” rating and a $30.00 target price on the stock. Bank of America initiated coverage on CeriBell in a research report on Tuesday, November 5th. They set a “buy” rating and a $32.00 target price on the stock. JPMorgan Chase & Co. initiated coverage on CeriBell in a report on Tuesday, November 5th. They issued an “overweight” rating and a $32.00 price target for the company. Finally, TD Cowen raised their price objective on CeriBell from $31.00 to $36.00 and gave the company a “buy” rating in a report on Monday, December 9th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $32.60.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.